Kairos Pharma
CompanyUnited States
Kairos Pharma develops one asset, in phase 2 (carotuximab in metastatic castration-resistant prostate cancer). Mostly antibody acting on ENG; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 0
- Signals
Pipeline
1Monoclonal antibody targeting endoglin (CD105) to address drug resistance in cancer
Phase 2, Antibody, ENG, metastatic castration-resistant prostate cancer
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Similar companies2